its all about the convertible debentures. Shorts are betting on MNKD not being able to repay the loan, refinance it or obtain favorable terms. The premise is that sales will not produce income in time to retire the debt. Their goal is to depress the stock price to make a shelf offering unattractive as a means of retiring the note. Also the BOA stock loan is like walking up and down wall st with a sandwichboard that says "short mnkd"
Apparently BMRN isn't claiming that dystrophin is produced by their drug, just that it prevents disease progression. If the patent covers exon skipping, wouldn't the method in the claim have to produce dystrophin in order to be protected by their patent?
Company is reorganized under a new charter and ticker symbol with 10 shares of mnkd redeemable for 1 share in the new company. Owners of record have 30 days to redeem/exchange their shares.
accumulation. Bid it up to create liquidity, sell it off to bring VWAP down so you can meet the execution promise for your buyer. I'd say the buyer wants a block under 6.
So what do you want, a buyback? MNKD focus is and should be execution. Not distraction wrt stock price or even other applications of TS. Conquer, Fortify, Domesticate.
After analyzing the short volume I came to the conclusion; that the recent FTD's are actually the result of covering as evidenced by short trades falling before going on the threshhold list.
I agree. Metformin reduces BS when you're not eating by inhibiting gluconeogenisis. It lowers the baseline. Now add Afrezza to control the spikes when you eat.
IMO that's the only reason to own Drisaperson. Their strategy is to file first get the voucher and then sell it along with their patent rights.
The problem at this point in analyzing growth is that there is a run-in period. You should probably be throwing out the first month or two. The counter argument is that we are still in a run in period. But the notion of quantizing the weeks has some merit. I was taught to collect data, analyze, visualize and then try to interpret the data in the context of the processes the data represents. It is tempting to manipulate the data in ways that make it support your hypotheses.
generally doctors don't schedule appointments ad hoc. Either the patient asks for one or a followup is scheduled with a visit. DTC is what will drive new encounters. Physician preference affects patients in the existing schedule.
The last 2 weeks show an increasing divergence from an exponential fit. It has been a rather stepped progression so there's still hope that changes in the driving forces will alter the trajectory. The questions at this point are still whether 600 scripts/week at the end of the year is good enough, and whether the marketing campaign will convert linear growth into exponential.